Want to see CYAN full AI Analyst Report?
Cyanotech (CYAN) AI Stock Analysis
Top Page
Cyanotech
(Other OTC:CYAN)
The overall score is driven primarily by weak but gradually improving financial performance, as Cyanotech remains loss‑making with elevated leverage and fragile, only recently positive cash flows. This risk is partly offset by a constructive technical picture, with the share price in a clear uptrend and momentum supportive without showing overbought extremes. Valuation adds limited support due to the deeply negative P/E ratio and lack of dividend yield, indicating that investors are pricing in a turnaround that has not yet been firmly validated by sustained profitability.
Cyanotech (CYAN) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $4.51M
- Dividend Yield
- ―
- Average Volume (3M)
- 7,100
- Price to Earnings (P/E)
- -67.8
- Beta (1Y)
- 0.28
- Revenue Growth
- 12.83%
- EPS Growth
- 97.83%
- Country
- US
- Employees
- 83
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
Cyanotech Business Overview & Revenue Model
Company Description
Established in 1983 and headquartered in Kailua-Kona, Hawaii, Cyanotech Corporation specializes in the global cultivation, processing, and distribution of natural products derived from microalgae. Its key product offerings include BioAstin Hawaiian A...
How the Company Makes Money
Cyanotech makes money primarily by producing and selling microalgae-based products through two main commercial paths: (1) bulk ingredient sales and (2) branded/packaged consumer products. Bulk ingredient revenue comes from supplying natural astaxanth...
Cyanotech Earnings Call Summary
The earnings call presented a mixed picture with notable growth in contract extraction revenue and improved inventory and capital metrics. However, significant declines in net sales, gross profit margin, and an increased net loss, largely due to inventory challenges, highlight ongoing challenges.
Q2-2025 Updates
Positive Updates
Negative Updates
Company Guidance
In the earnings call for Cyanotech's Q2 2025, management highlighted several key metrics and provided guidance on future performance. Despite a 39% increase in bulk inventory sales and a 156% rise in contract extraction revenue, overall sales for the quarter dropped by 8% due to a 21% decline in packaged goods sales caused by stock shortages. For the first half of the year, sales were up by 2%. Total net sales for the quarter were $5.8 million, down from $6.4 million in Q2 2024, with a gross profit margin declining from 32.8% to 25.3%, driven by a higher sales mix of lower-margin bulk products. Operating loss increased to $975,000 from $632,000 in the previous year, and net loss was $1.15 million or $0.16 per diluted share, compared to $0.8 million or $0.13 per share in Q2 2024. The company reported cash reserves of $780,000 and an improved working capital of $550,000, attributed to higher inventories and a short-term debt reclassification. Management is focused on addressing inventory challenges to improve the sales mix and maintain strong sales in their algae-based products.
Cyanotech Financial Statement Overview
Summary
Revenue has stabilized and returned to mid‑single‑digit growth with materially better gross margins, but the company remains structurally unprofitable, highly leveraged, and only recently modestly cash‑flow positive, so the financial profile still sits in a high‑risk early‑stage recovery phase.
Income Statement
32NegativeBalance Sheet
28NegativeCash Flow
24Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.44M | 26.59M | 24.21M | 23.07M | 23.18M | 35.97M |
| Gross Profit | 5.13M | 8.67M | 6.88M | 5.95M | 7.26M | 13.57M |
| EBITDA | 1.52M | 1.31M | -629.00K | -2.51M | -825.00K | 4.50M |
| Net Income | 289.00K | -1.28M | -3.20M | -5.27M | -3.44M | 2.15M |
Balance Sheet | ||||||
| Total Assets | 21.86M | 22.13M | 23.49M | 25.11M | 29.73M | 32.05M |
| Cash, Cash Equivalents and Short-Term Investments | 1.09M | 810.00K | 257.00K | 707.00K | 974.00K | 2.59M |
| Total Debt | 11.37M | 11.60M | 11.56M | 10.90M | 11.17M | 9.00M |
| Total Liabilities | 13.88M | 14.46M | 14.61M | 13.30M | 13.38M | 12.56M |
| Stockholders Equity | 7.99M | 7.66M | 8.88M | 11.81M | 16.35M | 19.49M |
Cash Flow | ||||||
| Free Cash Flow | 408.00K | 92.00K | -1.44M | -836.00K | -3.17M | 1.11M |
| Operating Cash Flow | 531.00K | 234.00K | -1.19M | -455.00K | -2.10M | 2.38M |
| Investing Cash Flow | -123.00K | -142.00K | -247.00K | -381.00K | -1.07M | -1.27M |
| Financing Cash Flow | 142.00K | 461.00K | 990.00K | 569.00K | 1.55M | -2.29M |
Cyanotech Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYAN, the sentiment is Positive. The current price of 0.61 is below the 20-day moving average (MA) of 0.64, above the 50-day MA of 0.53, and above the 200-day MA of 0.46, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 52.23 is Neutral, neither overbought nor oversold. The STOCH value of 53.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYAN.
Cyanotech Risk Analysis
Cyanotech disclosed 30 risk factors in its most recent earnings report. Cyanotech reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksCyanotech Peers Comparison
Overall Rating
SENEA87Outperform
LSF55Neutral
NATR51Neutral- CYAN47Neutral
USNA47Neutral
HAIN37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SENEA | 87Outperform | $1.08B | 9.14 | 16.36% | ― | 12.46% | 177.68% |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| LSF | 55Neutral | $28.43M | -6.31 | -11.36% | ― | 73.26% | -239.94% |
| NATR | 51Neutral | $215.55M | 12.01 | 11.00% | ― | 6.77% | 34.53% |
| CYAN | 47Neutral | $4.51M | -67.77 | -0.87% | ― | 12.83% | 97.83% |
| USNA | 47Neutral | $264.40M | -11.86 | -4.16% | ― | 1.57% | -166.61% |
| HAIN | 37Underperform | $10.84M | -0.04 | -106.47% | ― | -13.23% | 43.34% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CYAN | Cyanotech Corporation | 0.61 | 0.30 | 97.09% | |
| NATR | Nature's Sunshine Products | 12.25 | -1.51 | -10.97% | |
| SENEA | Seneca Foods | 159.78 | 55.54 | 53.28% | |
| HAIN | The Hain Celestial | 0.12 | -0.99 | -89.28% | |
| USNA | USANA Health Sciences Inc | 14.31 | -6.94 | -32.66% | |
| LSF | Laird Superfood, Inc. | 2.54 | -2.37 | -48.27% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026